Advanced viral gene therapy eradicates prostate cancer in preclinical experiments
Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer’s growth.
Chat on colorectal cancer
In honor of Colorectal Cancer Awareness Month, ABC News National Health hosted a Twitter chat on the subject last week with everyone from clinicians to patients providing commentary. VCU Massey Cancer Center’s medical oncologist Khalid Matin, M.D., F.A.C.P., was able to answer questions and elaborate on the discussion topics posed by the moderator. An expert in gastrointestinal cancers, Matin is also the medical director of community oncology and clinical research affiliations at VCU Massey Cancer Center and an associate professor in the Division of Hematology, Oncology and Palliative Care in the Department of Internal Medicine at the VCU School of Medicine.
Chat on the emotional side of healing
The Emotional Side of Healing was the subject of ABC News National Health’s weekly Twitter chat this past week, and patients, caregivers and clinicians were all asked to weigh-in on this area of interest. VCU Massey Cancer Center’s Egidio Del Fabbro, M.D., program director of palliative care, and Danielle Noreika, M.D., medical director of inpatient palliative care services, provided expert commentary as the moderator posed a series of questions and discussion topics.
Massey scientists contribute to research involving the latest FDA-approved cancer therapies
VCU Massey Cancer Center doctors and scientists are making important discoveries involving cancer-fighting drugs recently approved by the U.S. Food and Drug Administration (FDA). Between August 2013 and July 2014, the FDA approved six new anticancer therapeutics, five of which target the unique molecular and genetic characteristics of an individual’s cancer.
Massey researchers co-lead global breast cancer trials
Massey researchers are part of two international leadership teams recruiting subjects for phase 3 clinical trials testing novel breast cancer therapies. The first trial, known as KATHERINE, will test the efficacy and safety of a new antibody-drug conjugate, trastuzumab emtansine (T-DM1), in comparison to the standard FDA-approved drug Herceptin as post-operative, or “adjuvant”, therapy for early stage Human Epidermal Growth Factor Receptor 2-positive (HER2+) breast cancer patients. The second trial, OlympiA, will test the efficacy of the drug olaparib as adjuvant therapy for high risk, triple negative breast cancer patients with inherited loss of the BRCA1 or BRCA2 cancer suppressor genes.